Intellia submitted its first in vivo CRISPR-based gene editing therapy to the FDA, marking a regulatory milestone for direct delivery approaches. The filing signals continued expansion of genome editing beyond ex vivo formats toward systemic or in vivo targeting. For the gene editing sector, the FDA interaction is a key gating item for platform credibility and future program pacing, as regulators focus on delivery, durability, and safety characterization. Additional details on indication and clinical data were not included in the provided snippet, but the move itself places Intellia’s program into an active review pathway.